Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 33

Results For "Head"

1959 News Found

FDA approves Merck's Keytruda injection for cancer therapy
Drug Approval | September 21, 2025

FDA approves Merck's Keytruda injection for cancer therapy

Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute


Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration
News | September 19, 2025

Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration

This predictive technology empowers people with diabetes to take preventive action before complications arise


CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar
Clinical Trials | September 19, 2025

CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar

Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints


Bayer inaugurates new phytomedicines lab facility
News | September 18, 2025

Bayer inaugurates new phytomedicines lab facility

The lab will facilitate the development of herbal and natural-based solutions


Bayer launches biotech innovation platform in China
Startup | September 17, 2025

Bayer launches biotech innovation platform in China

Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks


GSK to invest $30 billion in R&D, manufacturing in US over next 5 years
News | September 17, 2025

GSK to invest $30 billion in R&D, manufacturing in US over next 5 years

Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs


FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers
Drug Approval | September 16, 2025

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo


Drug Hunter secures seed investment to scale drug discovery knowledge platform
R&D | September 16, 2025

Drug Hunter secures seed investment to scale drug discovery knowledge platform

Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management